Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board’s Freedom of Information Office at https://www.federalreserve.gov/foia/request.htm. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than April 22, 2021.

A. Federal Reserve Bank of Minneapolis (Chris P. Wangen, Assistant Vice President), 90 Hennepin Avenue, Minneapolis, Minnesota 55480–0291:

1. Steven Clevidence, Stevensville, Montana; the ICC Heritage Trust and the MG Holdings Trust; Ryan Clevidence, as trustee, the Groff Heirloom Trust and the IW Holdings Trust; Sara Clevendence Waldbillig, as trustee, all of Lolo, Montana; and Shane Beely, as trust protector of each of the foregoing trusts, Missoula, Montana; to join the Groff-Clevendence family control group, a group acting in concert, to retain voting shares of Farmers State Financial Corp., and thereby indirectly retain voting shares of Farmers State Bank, both of Victor, Montana.


Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2021–07160 Filed 4–6–21; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)-PAR 21–165, Underground Mine Evacuation Technologies and Human Factors Research.

Date: June 3, 2021.

Time: 1:00 p.m.–3:00 p.m., EDT.

Place: Video-Assisted Meeting.

Agenda: To review and evaluate grant applications.

For Further Information Contact:
Marilyn Ridenour, B.S.N., M.B.A., M.P.H., C.P.H., C.I.C., CAPT, USPHS, Scientific Review Officer, Office of Extramural Programs, National Institute for Occupational Safety and Health, CDC, 1095 Willowdale Road, Morgantown, West Virginia 26505, Telephone (304) 285–5879; MRidenour@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021–07162 Filed 4–6–21; 8:45 am]
communities to vaccinate people with disabilities. For example, some people with disabilities may experience difficulties scheduling appointments, communicating, obtaining accessible transportation or require direct support services to attend vaccination appointments. Others living in the community may be isolated or unable to leave their home and may require in-home vaccination.

This funding opportunity is designed to breakdown those barriers to expand vaccine access in communities. Examples of activities consistent with the purpose of this funding are the following:
- Education about the importance of receiving a vaccine,
- Identifying people unable to independently travel to a vaccination site,
- Helping with scheduling a vaccine appointment,
- Arranging or providing accessible transportation,
- Providing companion/personal support,
- Reminding people of their second vaccination appointment if needed, and/or
- Providing technical assistance to local health departments or other entities on vaccine accessibility.

Awards authorized under Subtitle D of the DD Act, University Centers for Excellence in Developmental Disabilities (UCEDDS), shall be provided funding under this opportunity. Award recipients will be required to submit annual progress reports on the activities conducted, challenges, successes, and lessons learned and provide a written summary. In addition, to show impact of the grant awards, the grantee will include the number of people served or impacted by the services provided against each of the activities chosen to be implemented. To be eligible to receive this grant, the grantee must submit a Letter of Assurance to ACL containing all of the assurances required, see below, “Section III. Eligibility Criteria and Other Requirements” and “Section IV. Submission Information”). UCEDDs who do not complete assurance requirements below, or otherwise indicate no desire to receive funds will be excluded from receiving funds.

ACL may establish ad hoc dates based on the need of the COVID–19 response, e.g., to meet unanticipated issues related to COVID–19 and/or to allow impacted eligible applicants that missed the cut-off date to submit an application for consideration. ACL intends to issue initial notices of award as applications are received prior to the application due date to address urgent COVID–19 response needs. Second notices of award are planned after the actual number of applicants is finalized.

II. Award Information
1. Funding Instrument Type
   These awards will be made in the form of grants to UCEDDs.

2. Anticipated Total Funding per Budget Period
   Under this program announcement, ACL intends to make grant awards to each State and territory, and the District of Columbia. Awards made under this announcement have an estimated start date of April 1, 2021 and an estimated end date of September 30, 2022, for a 17-month budget and performance period.

   The total available funding for this opportunity is $4,000,000. Funding will be distributed evenly across the states and territories to the 67 UCEDD grantees. The projected amount for each award is $59,701.

III. Eligibility Criteria and Other Requirements
1. Eligible Entities
   The eligible entity for these awards is the agency designated as a UCEDD in each state or territory.

2. Other Requirements
   A. Letter of Assurance
      A Letter of Assurance is required to be submitted by the eligible entity in order to receive an award. The Letter of Assurance must include the following:
      1. Assurance that the award recipient is the agency or entity designated as UCEDD in the state or territory.
      2. Assurance that funds will supplement and not supplant existing UCEDD funding.
      3. Assurance that funds will be spent in ways consistent with the purpose of the funding in carrying out one or more of the following activities:
         - Education about the importance of receiving a vaccine,
         - Identifying people unable to independently travel to a site,
         - Helping with scheduling a vaccine appointment,
         - Arranging or providing accessible transportation,
         - Providing companion/personal support,
         - Reminding people of their second vaccination appointment if needed, and/or
         - Providing technical assistance to local health departments or other entities on vaccine accessibility.

   B. DUNS Number
      All grant applicants must obtain and keep current a D-U-N-S number from Dun and Bradstreet. It is a nine-digit identification number, which provides unique identifiers of single business entities. The D-U-N-S number can be obtained from: https://iupdate.dnb.com/iUpdate/viewUpdateHome.htm.

   C. Intergovernmental Review
      Executive Order 12372, Intergovernmental Review of Federal Programs, is not applicable to these grant applications.

IV. Submission Information
1. Instructions for completing the application will be available from the ACL Project Officer.

   The following table identifies the designated program officer against each of the 10 ACL regions:

<table>
<thead>
<tr>
<th>ACL regions</th>
<th>Email/phone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pam O’Brien, Program Officer</td>
</tr>
<tr>
<td>Region I: CT, MA, ME, NH, RI, VT ..........</td>
<td><a href="mailto:pamela.obrien@acl.hhs.gov">pamela.obrien@acl.hhs.gov</a>, 202–795–7417.</td>
</tr>
<tr>
<td>Region II: NY, NJ, PR, VI.</td>
<td></td>
</tr>
<tr>
<td>Region III: DC, DE, MD, PA, VA, WV.</td>
<td></td>
</tr>
<tr>
<td>Region IV: AL, FL, GA, KY, MS, NC, SC, TN.</td>
<td></td>
</tr>
<tr>
<td>Region VI: AR, LA, OK, NM, TX.</td>
<td></td>
</tr>
</tbody>
</table>
2. Submission Dates and Times

To receive consideration, applications must be submitted by 11:59 p.m. Eastern Time on April 21, 2021, through www.GrantSolutions.gov.

VII. Agency Contacts

1. Programmatic Issues

Direct programmatic inquiries to your program officer:

ACL Regions I, II, III, IV, and VI, Pamela O’Brien, Email: Pamela.Obrien@acl.hhs.gov, Phone: 202–795–7417
ACL Regions V, VII, VIII, IX, and X, Shawn Callaway, Email: Shawn.Callaway@acl.hhs.gov, Phone: 202–795–7319

2. Submission Issues

Direct inquiries regarding submission of the Letters of Assurance to the appropriate ACL Program Officer found in the table in “Section IV. Submission Information.”

Dated: April 1, 2021.

Alison Barkoff,
Acting Administrator and Assistant Secretary for Aging.

[FR Doc. 2021–07128 Filed 4–6–21; 8:45 am]
BILLING CODE 4154–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Community Living

Availability of Program Application Instructions for the State Councils on Developmental Disabilities To Expand COVID–19 Vaccine Access for People With Disabilities

Title: Expanding Disabilities Network’s (DD Councils) Access to COVID–19 Vaccines

Announcement Type: Initial


Catalog of Federal Domestic Assistance (CFDA) Number: 93.630.

DATES: The deadline date for the submission of the Expanding Disabilities Network’s (DD Councils) Access to COVID–19 Vaccines is 11:59 p.m. April 21, 2021.

SUPPLEMENTARY INFORMATION:

I. Funding Opportunity Description

The Administration for Community Living (ACL) announced a new funding opportunity to increase vaccine access for people with disabilities. With funding and partnership support from the Centers for Disease Control and Prevention (CDC), ACL is providing grants to disability networks to provide critical services to help communities combat COVID–19. A leading priority of this joint effort is to ensure vaccines are equally accessible to the disability population.

Approximately 61 million adults living with in the U.S. have a disability, representing approximately 26 percent of the adult population. People with disabilities may have an increased risk for contracting COVID–19 based on where they live or the services they receive. Some people with disabilities live in group settings which places them at higher risk for acquiring COVID–19 in comparison to people without disabilities. People with disabilities may also require close contact with direct service providers, including personal care attendants or other care providers, who help with activities of daily living. Moreover, many people with disabilities have underlying health conditions (e.g., diabetes, heart disease, and obesity) that increases the risk of severe illness due to COVID–19. In addition, research has also found that people with Down Syndrome are significantly more likely to be hospitalized from COVID–19 than the general population.

There are increasing reports of barriers and unequal access in communities to vaccinate people with disabilities. For example, some people with disabilities may experience difficulties scheduling appointments, communicating, obtaining accessible transportation or require direct support services to attend vaccination appointments. Others living in the community may be isolated or unable to leave their home and may require in-home vaccination.

This funding opportunity is designed to breakdown those barriers to expand vaccine access in communities. Examples of activities consistent with the purpose of this funding are the following:

- Education about the importance of receiving a vaccine,
- Identifying people unable to independently travel to a vaccination site,
- Helping with scheduling a vaccine appointment,
- Arranging or providing accessible transportation,
- Providing companion/personal support,
- Reminding people of the second vaccination appointment if needed, and/or
- Providing technical assistance to local health departments or other entities on vaccine accessibility.

Awards authorized under Subtitle B of the DD Act, State DD Councils, shall be provided funding under this opportunity. Award recipients will be required to submit annual progress reports on the activities conducted, challenges, successes, and lessons learned and provide a written summary. In addition, to show impact of the grant awards, the grantees will include the number of people served or impacted by the services provided against each of the activities chosen to be implemented. To be eligible to receive this grant, the grantee must submit a Letter of Assurance to ACL containing all of the assurances required, (see below, “Section III. Eligibility Criteria and Other Requirements” and “Section IV. Submission Information”). DD Councils who do not complete assurance requirements below, or otherwise indicate no desire to receive funds will be excluded from receiving funds.

ACL may establish ad hoc dates based on the need of the COVID–19 response, e.g., to meet unanticipated issues related to COVID–19 and/or to allow impacted eligible applicants that missed the cut-off date to submit an application for consideration. ACL intends to issue initial notices of award as applications are received prior to the application due date to address urgent COVID–19 response needs. Second notices of award are planned after the actual number of applicants is finalized.

II. Award Information

1. Funding Instrument Type

These awards will be made in the form of formula grants to State DD Councils.